Brought to you by 
Hikma gets license to Basilea's Zevtera, Cresemba in MENA region
13 Aug 2018
Executive Summary
Basilea Pharmaceutica Ltd. licensed Hikma Pharmaceuticals PLC exclusive rights to register, distribute, and commercialize its broad-spectrum antibiotic Zevtera (ceftobiprole medocaril) in the Middle East and North Africa region.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hikma gets license to Basilea's Zevtera, Cresemba in MENA region
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice